Cytokinetics, a South San Francisco-based biopharmaceutical company, develops muscle activators and inhibitors for diseases affecting muscle performance, with key drug candidates including aficamten and omecamtiv mecarbil. Founded in 2004, it employs 423 people and specializes in cardiac muscle function.
CYTK has been in the news recently: Multiple law firms, including Rosen Law Firm and the Gross Law Firm, have initiated a class action lawsuit against Cytokinetics, Inc. for stock purchasers between December 27, 2023, and May 6, 2025, with a deadline for lead plaintiffs set for November 17, 2025. Additionally, DJS Law Group is informing investors about the lawsuit due to alleged misleading statements made by Cytokinetics during the same time period.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
